Sun Pharma Advanced Research Company Ltd has officially announced a board meeting scheduled for Monday, May 18, 2026. The primary objective of this assembly is to review and approve the company’s audited standalone and consolidated financial results for the quarter and financial year ending March 31, 2026.
Reviewing Annual Performance
The leadership team at Sun Pharma Advanced Research Company is set to convene on May 18, 2026, to evaluate the organization’s fiscal health. The session will focus on the audited financial statements for the fourth quarter and the full financial year concluded on March 31, 2026. This meeting marks a significant milestone in finalizing the company’s annual reporting for the fiscal year.
Trading Window Restrictions
In accordance with the organization’s internal governance policies, the trading window for company shares remains restricted. This closure, which began on April 01, 2026, applies to all directors, key managerial personnel, and designated employees. Access to trade will resume 48 hours after the official declaration and submission of the financial results to the stock exchanges, ensuring transparency during the period of financial disclosure.
Source: BSE
